Aug. 15 Company Quick Takes: IQVia's patient portal; plus Gilead/Galapagos and GeneCentric/Select ImmunoGenomics

IQVia launches patient portal
IQVia Holdings Inc. (NYSE:IQV) launched a cloud-based patient portal designed to reduce clinical trial costs associated with patient dropout or lack of follow-up. The platform increases patient engagement with clinical guides, reminders and education; access to lab results and other study information; and creation of patient communities for future trials. The company will provide the portal as a stand-alone service or integrated with other clinical trial services.

Filgotinib under review for RA in Europe
Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said EMA has accepted for review an MAA for filgotinib to treat adults with rheumatoid arthritis. Gilead gained exclusive, worldwide rights to the oral Janus kinase-1 inhibitor for inflammatory diseases from Galapagos in December 2015 and plans to submit an NDA to FDA this year (see "Filgotinib Hits More RA Endpoints")...